INTRODUCTION
P rostate-specific antigen (PSA) is a kallikrein-like serine protease produced by the epithelial cells of the prostate and male urethra 1, 2 . The serum levels of PSA may be elevated in the presence of benign prostatic hypertrophy (BPH), prostatitis and other non-malignant conditions. So, it is said that PSA is organ-specific but not cancer-specific. Although the level of PSA as an independent variable is a better predictor of PCa than suspicious findings on DRE or TRUS 3 , PSA lacks specificity and sensitivity for the ideal tumor marker. Moreover, PSA level cannot predict tumor volume and stage; there is a great percent of tumors with PSA lower than historical upper limit of 4.0 ng/ml. Today, it is clear that there is no optimal PSA threshold value for detecting non-palpable, but clinically significant PCa. In addition, there is no universally accepted cut-off or upper limit: PSA is a continuous parameter: the higher the value, the more likely is the existence of PCa (Table 1. ) 4, 5 .
PROSTATE SPECIFIC ANTIGEN: THE MAIN PROD-UCT OF THE PROSTATE SECRETION
Prostate specific antigen is the main product of the prostate secretion. Normal prostate contains 100 mg of PSA. Average PSA concentration in seminal plasma is 0.3-3 mg/mL [6] [7] [8] . Prostate specific antigen was detected for the first time in the seminal plasma, in 1966; its first use was the identification of rape victims 9, 10 . Later, in the 1981, Wang predicted the potential use of PSA as a prostate tumor marker 11 .
PROSTATE SPECIFIC ANTIGEN IN THE PROSTATIC CELLS
The PSA molecule is a glycoprotein with 240 amino acids. The molecular weight of PSA is 34 kDa. The gen for PSA is located on XIX chromosome, near the genes for pancreatic and glandular kallikrein (hK1and hK2). The synthesis of PSA is influenced by testosterone, adrenal androgens and dihydrotestosterone (DHT). Treatment with either testosterone or DHT in LNCaP cells produces dose and time-dependent increases in PSA levels in the cell media and in PSA messenger RNA (mRNA) levels in . After the synthesis in cytosol, PSA molecules are stored in prostatic secretory granules (PSG). These granules, 1 µ in diameter, fulfill the cytosol; during so called apocrine decapitation, great numbers of PSGs are emptied from the cell to the prostatic acini lumina 13 . Average PSA concentration in prostatic tissue is 15 mg per gram of tissue, as calculated by Kuriyama 14 . However, the expression of PSA is the highest in the epithelial cells of BPH, moderate in normal epithelial cells and the lowest in PCa cells. In addition, PSA expression is higher in well-differentiated PCa cells, than in poor-differentiated high-grade PCa cells [14] [15] [16] [17] [18] [19] [20] [21] .
THE TRANSFER OF PSA MOLECULES INTO PRO-STATIC DUCTS AND THE BLOOD
Prostatic epithelial cell secretes precursors of PSA into the lumen. This precursor is called pro-PSA, with 244 amino acids and it is enzymatically inactive. In the lumina, hK2 removes polypeptide and transforms pro-PSA into active PSA. Active molecules pass into the circulation, where they are quickly bounded with alpha-1-antichymotripsine (ACT). However, one percentage of active PSA molecules underwent proteolysis and become inactive; these inactive molecules are detected in blood as free PSA.
In normal prostate, PSA molecules enter the circulation throw the prostate-blood barrier, consisted of basal cells, basal membrane, stroma, capillary basal mem-brane and endothelial cells. The common reason for in-creased PSA shunting into the blood is the damage of pro-state-blood barrier; so, increased serum PSA often follows acute inflammations of the prostate 22 , prostate cancer, prostate infarct and various prostatic tissue traumas, like after biopsy or surgery.
In PCa, the damage is located mo-st probably around the tumor and followed by PSA lea-kage of PSA from extracellular space, dead cells and rup-tured acini to small prostatic or tumor-induced blood vessels 23 . The decreased concentration of free PSA molecules in PCa is the consequence of the same process; due to damaged prostate-blood barrier, the "maturation" of PSA is impaired and just a small percent of PSA is processed into inactive forms. Thus, the larger percent of active molecules enter the circulation where they are almost immediately bounded by ACT
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. The average half-life of PSA in plasma is 65 hours 25, 26 .
THE FACTORS THAT INFLUENCE ON PSA BLOOD CONCENTRATION
All factors that could influence on PSA blood concentration can be divided into three categories: factors related to tumor, prostate and the patient.
Factors related to tumor
The factors related to tumor that influence on PSA blood level are tumor volume, tumor growth rate and tumor histological type.
Tumor volume
Tumor volume is very important parameter; Stamey was the first that estimated the average PSA/tumor volume ratio of 3.6 ng PSA per milliliter of the tumor, although some other authors had different results 27, 28 . However, this model had significant errors in the single patient evaluation. As PCa secretes low amounts of PSA, it is not the source of elevated PSA, but the damaged tissue around the tumor. In addition, tumors with equal volumes could be associated with various and very different PSA values 29 .
Tumor position
The majority of PCa rise in peripheral zone, due to its richness in glandular elements 30 . It is proved that centrally positioned tumors have higher PSA than its peripheral counterparts 27 . Possibly, central tumors have more neighboring epithelial tissue than peripheral ones. 30 . In addition, tumor grade or cell differentiation is related to tumor volume: the larger the tumor, it is older and therefore, with more poorly differentiated cells. Following this concept, there is no tumor latency; the "latency" is the consequence of small volume and late beginning of the malignant process. For example, if the average tumor doubling time is three years 27 , 30 years are needed for the growth of 1 ml-volume tumor, from the first malignant transformation. It is known that high-grade intraepithelial neoplasia (HG-PIN) is discovered in the very young men, in the third de-cade of life 31 . Conversely, if the first malignant transformation takes place in the man aged 50-60 years, probably he will not live so long to develop significant PCa.
Factors related to the prostate
The prostate is glandular organ with intracrine activity and the synthesis of its own hormone, DHT, from testosterone and adrenal androgens. In BPH, due to increased DHT activity, the synthesis of PSA is increased and PSA=1.6 ng/ml is significant predictor of the progression of the BPH [32] [33] [34] . In addition, the PSA concentration in urine is also associated with BPH [35] [36] [37] [38] . The reason for elevation of serum PSA in patients with BPH is more likely DHT hyperactivity and PSA synthesis, than PSA production in hyperplastic, mainly stromal, transition zone. As the majority of glands are localized in the peripheral zone (PZ), it is the main origin of the elevated PSA in BPH. If the PCa appears in the PZ rich in PSA, its growth will follow significant increase of PSA concentration.
Factors related to the patient
It seems that hormonal milieu does not affect PSA production. Namely, older men that have BPH, PCa or both diseases, usually have low serum testosterone, but normal or elevated DHT 39 . Elevated DHT levels are probably correlated with decreased serum testosterone [40] [41] [42] . The second factor is the total blood volume. As the blood volume is 7% of total body weight 43 , a man weighted 60kg has 4.2L of blood, while man weighted 120kg has 8.4L of blood. That means, if both men have PSA level of 3.0ng/ml, the heavier man has double amount of PSA than his smaller counterpart.
METHODS
The mathematical model was used in the attempt to explain the great varieties in PSA values, emerged due to various factors and conditions. At first, it was necessary to enter various theoretical mathematical data, like prostatetumor model, "destruction zone around the tumor" (DZT), position of the tumor, prostate volume, DZT volume etc.
Prostate-tumor model
The prostate and the tumor were presented like ideal spheres. Destruction zone around the tumor (DZ)
The DZ is the model of PSA-containing tissue around the tumor; it is defined as the volume inside the prostate, which represents the difference between two concentric spheres (Fig. 1) .
Tumor volume
Various tumor models were entered, with volumes ranged continuously from 0.01 ml to 15ml.
FIGURE 2: THE TUMOR MODEL THAT PENETRATES THE CAP-SULE OF THE PROSTATE MODEL: DZ LACKS ONE PART OUT OF THE PROSTATE, BECAUSE THERE IS NO PSA-CONTAINING TISSUE OUTSIDE THE PROS-TATE. (R=RADIUS OF THE PROSTATE MODEL, C=CENTER OF THE PROSTATE, C=CENTER OF THE TUMOR, D=DISTANCE BETWEEN C AND C) FIGURE 3: THREE IDENTICAL TUMORS, A, B AND C HAVE DIF-FERENT PSA VALUES DUE TO DIFFERENT DZ VOL-UMES. TUMOR C HAS THE LOWEST DZ VOLUME AND THEREFORE, THE LOWEST PSA VALUE.
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The position of the tumor in the prostate
Five points were chosen to represent the center of the growth of the tumor models: r/6, 2r/6, 3r/6, 4r/6 and 5r/6, from the center of the prostate model (C) (Fig. 2) .
The shape and the volume of the DZ depend on the volume and the position of the tumor: identical tumors can be followed by different PSA levels, due to different volumes of their DZ. (Fig. 3.) 
Prostate volume
The different volumes of the prostate model were entered into the calculation: 20ml, 40ml, 60ml, 80ml, 100ml and 120ml.
The calculation of DZ volume Mr. A. Marjanovic is the author of the software for this mathematical model. The model included general geometrical formulas for the calculations of sphere volumes, and complex equations for the calculation of the calotte, transverse spherical section, section bases and coordinates of intersection of inner spheres and outer sphere.
The growth of the tumor model was analyzed using three possible volume-doubling rates of 2, 3 and 4 years. However, the interval t was constant and equals 65 hours, what is the average PSA half-life in the blood. Therefore, during 65 hours, tumor with volume-doubling time of 2 years produces greater DZ than the tumor with doubling time of 4 years.
The calculation of serum PSA concentration
From the calculated DZ volume, during 65 hours, PSA molecules with the average tissue concentration of 15 mg/ml enter the blood. This result was divided with 2, due to the value of PSA half-life in plasma, and with various blood volumes, in various virtual patients.
Various blood volumes and PSA concentration
Various blood volumes, i.e. body weight were entered into the calculation, ranging from 50kg, continuously to 100kg. The last calculation stresses the need for new PSA derivate, "weight-corrected PSA". It could be calculated as serum PSA multiplied with coefficient k: k= actual weight/70kg (average weight).
Graphical presentation
On the graphs, PSA serum concentrations are presented on the ordinate and tumor volumes on the abscissa. Every curve on the graph represents tumor volume to serum PSA ratio. Numerous curves represent various prostate volumes, from 20ml to 120ml. On the every particular graph, there is one body weight (i.e. blood volume) and one tumor-volume doubling time. In the graph 1, the patient weighted 70kg, with the prostate of 20ml and the tumor sized 5ml can have serum PSA of 8 ng/ml. On the other hand, the patient weighted 70kg, with the prostate of 120ml and the tumor of 5ml can have serum PSA of 20ng/ml.
RESULTS
The huge number of results and the combinations of different multiple parameters can be presented in the graphs; particular graphs than could be used for particular patient, according to his weight. The best match between graphical values and the literature data was achieved in the graphs with tumor doubling time of 3 years (Graph 2) 44 . The simpler graphs can be made with the use of minimal curve and the maximal curve. "Minimal curve" represents tumor volume/PSA ratio for the peripheral tumors, arising GRAPH 1: TUMOR-VOLUME DOUBLING TIME=3 YEARS, BODY WEIGHT=70KG. PSA RANGES FROM 0-40 NG/ML, TU-MOR VOLUME FROM 0-10 ML.
GRAPH 2: TUMOR-VOLUME DOUBLING TIME=3 YEARS. THE LOWEST CURVE IS MINIMAL CURVE, THE HIGHEST IS MAXIMAL CURVE. BETWEEN THEM LIES STAMEY'S LINEAR CURVE THAT REPRESENTS PSA/TUMOR VOLUME RATIO AND EQUALS 3.6 NG PER 1ML OF TUMOR. DOTS IN THE GRAPH REPRE-SENT PARTICULAR PATIENTS FROM THE PALKEN'S STUDY.
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T. Pej~i} et al. ACI Vol. LVIII from 5r/6 from the prostate model center (C), with the smallest prostates (20ml) and the highest body weights (100kg). Maximal curve represents tumor volume/PSA ratio for the central tumors, arising from r/6 from C, with the largest prostate (120ml) and lowest weight (50kg). The graphs enable virtual observation of tumor natural history and the rise of tumor volume and the PSA. It is consistent with epidemiological and clinical data that prostate tumors have long period to become "significant".
The graphs show that average period of tumor growth to the volume of 0.5ml (10 mm diameter) is 30 years. Thereafter, additional three years are needed to reach 1.0ml (12.5mm diameter).
DISCUSSION
The use of PSA dramatically changed prostate cancer (PCa) detection and treatment strategies. The definition of PSA cut-off of 4.0ng/ml made the PCa diagnosis very easy. Unfortunately, the great number of organ-confined PCa with PSA < 4.0ng/ml emerged, so the cut-off was lowered to 2.5ng/ml. However, new data show that the patients with PSA from 1.1-2.0ng/ml have the risk of harboring PCa of even 17%. So, adored urological marker started to lose its popularity! Some claimed that PSA era is finally completed and PSA-terror ended.
However, there are so many factors that could influence PSA concentration in blood. At the first place, some prostates are DHT-active and rich in PSA, while others are not. On the other side, there is a large number of men with late onset hypogonadism; in the USA, they comprise 43% of men aged = 65 years 45 . These men most probably have lower PSA values than their counterparts. Different tumor volumes also contribute to different PSA values, but not due to their own PSA production, but due to local influence on the surrounding PSA-producing tissue. It is well known that tumors which occupy entire peripheral zone of the prostate can be followed with surprisingly low PSA. In addition, different blood volumes may significantly influence PSA serum levels, due to dilution effect.
This mathematical model had the aim to show the variety of factors that can influence of PSA level; some of these factors can be practically applied, but there is lot of limitations, as well. At the first place, the position of the tumor or multiple tumors can be estimated. The center of the tumor and its volume and boundaries can be measured on whole-mount pathological specimen, as shown in the Fig. 4 .
Second, blood volume can be calculated for every patient from its body weight. The insufficiently clarified factors are tumor volume-doubling time, PSA tissue concentration and PSA half-life in plasma. While tumor doubling-time is still hard to measure, PSA half-life can be estimated more precisely. Moreover, tissue PSA could be obtained for every single patient from the biopsy specimen.
CONCLUSION
In the future, with the inclusion of all listed factors, the interpretation of PSA could be more precise and its sensitivity acceptable, again.
SUMMARY
Uvod: Koncentracija prostata specifi~nog antigena (PSA) u serumu kod lokalizovanog karcinoma prostate (PCa) zavisi od mnogih faktora. Ovi faktori se mogu podeliti na faktore vezane za tumor, prostatu i pacijenta. Tumorski faktori su zapremina tumora, lokalizacija i brzina rasta tumora. Faktori vezani za prostatu su zapre-GRAPH 3: TUMOR GROWTH THROUGH THE LONG PERIOD OF TIME. UPPER CURVE IS TUMOR VOLUME, MIDDLE IS MAXIMAL AND THE LOWEST IS MINIMAL CURVE. ON THIS GRAPH, THE MAJORITY OF TU-MORS < 1.0 ML HAVE PSA < 4.0NG/ML. 
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The analysis of some factors that influence on serum PSA 85 level in licalised prostate cancer patients mina prostate, aktivnost dihidrotestosterona (DHT) u prostati i ja~ina sinteze PSA. Faktori vezani za pacijenta su androgeni status i ukupna zapremina krvi.
Cilj rada: Analiza i diskusija svih navedenih faktora koji mogu da uti~u na nivo PSA kod lokalizovanog PCa. Takodje, predstaviti matemati~ki model koji predvidja koncentraciju PSA u serumu kod lokalizovanog PCa.
Metode: Matemati~ki model se zasniva na hipotezi da serumski PSA koji je posledica rasta tumora, poti~e iz epitelnih }elija iz neposredne blizine tumora, takozvane Zone destrukcije (DZ). Zapremina DZ zavisi od zapremine tumora, njegovog polo'aja u prostati i njegove brzine rasta. Sa druge strane, koli~ina PSA koja ulazi u krvotok zavisi od zapremine DZ i koncentracije PSA u DZ.
Rezultati: Ova studija nudi široki spektar vrednosti PSA u zavisnosti od karakteristika tumora, prostate i pacijenta. Ove vrednosti je mogu}e uporediti sa vrednostima iz literature. Najbolje slaganje sa podacima iz literature se dobija ako se za period udvostru~avanja zapremine tumora uzme period od tri godine.
Zaklju~ak: Uz izvesna ograni~enja, ovaj model mo'e da objasni velike raznolikosti koncentracije PSA u serumu.
Klju~ne re~i: matemati~ki model, karcinom prostate, zapremina tumora, polo'aj tumora
